Emavusertib hydrochloride is under clinical development by Aurigene Discovery Technologies and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Emavusertib hydrochloride’s likelihood of approval (LoA) and phase transition for Diffuse Large B-Cell Lymphoma took place on 21 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Emavusertib hydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Emavusertib hydrochloride overview

Emavusertib hydrochloride is under development for the treatment of diffuse large B cell lymphomas, relapsed or refractory follicular lymphoma, myelodysplastic syndrome, chronic lymphocytic leukemia., mantle cell lymphoma, primary CNS lymphoma, non-Hodgkin lymphomas such as Waldenstrom macroglobulinemia and marginal zone lymphoma, hematologic malignancies, gastric cancer, pancreatic ductal adenocarcinoma, melanoma, esophageal cancer and adenocarcinoma of the gastroesophageal junction, non-Hodgkin lymphomas such as myelodysplastic syndrome, chronic myelomonocytic leukemia (CMML) and chronic myelocytic leukemia (CML, chronic myeloid leukemia). It is a small molecule administered orally. The drug candidate targets interleukin-1 receptor-associated kinase-4 (IRAK-4) and FLT3 (FMS like tyrosine kinase 3). It was also under development for the treatment of rheumatoid arthritis and relapsed or refractory acute myelocytic leukemia.

Aurigene Discovery Technologies overview

Aurigene Discovery Technologies (Aurigene), a subsidiary of Dr. Reddy’s Laboratories Ltd, is a biotechnology company that develops small molecule and peptide therapeutics. The company develops small molecule and peptide drug candidates for oncology and inflammatory diseases. It owns integrated drug discovery infrastructure from hit generation to pre-clinical development. Aurigene’s pipeline portfolio consists of products for immunoncology PD-L1 and Vista, TIM-3 and PD1, CD47; precision oncology products IRAK4, NAMPT, KRAS, CDK7; Epigenetics products BET Bromodomain, PRMT5, CBP and P300; and inflammatory product ROR Inverse Agonist. It operates through collaboration with mid-pharma companies. Aurigene is headquartered in Bangalore, Karnataka, India.

Quick View Emavusertib hydrochloride LOA Data

Report Segments
  • Innovator
Drug Name
  • Emavusertib hydrochloride
Administration Pathway
  • Oral
Therapeutic Areas
  • Immunology
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.